THE ROLE RWE PLAYS IN HELPING PATIENT GROUPS AND THE PRIVATE SECTOR ACCELERATE ACCESS TO TREATMENT/SERVICES IN ASIA

As healthcare systems across Asia Pacific (APAC) start to gather more real-world evidence (RWE), this article takes a look at how patient groups and the wider healthcare community can come together through public and private partnerships and platforms such as the Alliance & Partnership for Patient Innovation & Solutions (APPIS), to incorporate RWE into health policy decision-making and better reflect patients’ needs. Clinical data has been traditionally used to inform healthcare choices, but looking at RWE, in all its forms, has become increasingly important in understanding the more holistic impact on patients.

How is RWE being used in APAC?

Healthcare systems across APAC are incredibly diverse. In recent years, we’ve seen markets with national healthcare systems increasingly incorporating RWE into practises, including post-market pharmacovigilance, testing innovative treatments, insurance reimbursement, clinical usage, and healthcare policy decision-making.

Taiwan, for instance, has comprehensive national databases, including the Taiwan National Health Insurance Research Database (NHIRD), as well as electronic medical records, hospitals’ medical records, national registries, and investigator-initiated studies. These sources of data contain comprehensive, large-scale records such as demographics, prescriptions, and treatments, all of which can be used as powerful sources to generate RWE and shape healthcare policies.

Early access zones can also expedite approvals for innovative medication. In China, pilot zones like Boao Lecheng have generated RWE to support the approval of new drugs from the United States and Europe for wider use in other areas of China, creating the opportunity to reduce or even avoid the need for further clinical trials. We’ve seen drugs to treat rare diseases being successfully approved in China using this pathway, and in other disease areas, RWE is being used in conjunction with clinical trials to obtain full approval.

Read complete article point to point about: THE ROLE RWE PLAYS IN HELPING PATIENT GROUPS AND THE PRIVATE SECTOR